Literature DB >> 25556638

Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?

Roslyn M Bill1.   

Abstract

OBJECTIVES: Recombinant protein subunit vaccines are formulated using protein antigens that have been synthesized in heterologous host cells. Several host cells are available for this purpose, ranging from Escherichia coli to mammalian cell lines. This article highlights the benefits of using yeast as the recombinant host. KEY
FINDINGS: The yeast species, Saccharomyces cerevisiae and Pichia pastoris, have been used to optimize the functional yields of potential antigens for the development of subunit vaccines against a wide range of diseases caused by bacteria and viruses. Saccharomyces cerevisiae has also been used in the manufacture of 11 approved vaccines against hepatitis B virus and one against human papillomavirus; in both cases, the recombinant protein forms highly immunogenic virus-like particles.
SUMMARY: Advances in our understanding of how a yeast cell responds to the metabolic load of producing recombinant proteins will allow us to identify host strains that have improved yield properties and enable the synthesis of more challenging antigens that cannot be produced in other systems. Yeasts therefore have the potential to become important host organisms for the production of recombinant antigens that can be used in the manufacture of subunit vaccines or in new vaccine development.
© 2014 Royal Pharmaceutical Society.

Entities:  

Keywords:  Pichia pastoris; Saccharomyces cerevisiae; recombinant antigen; yeast

Mesh:

Substances:

Year:  2014        PMID: 25556638     DOI: 10.1111/jphp.12353

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  15 in total

Review 1.  Recent advances in the production of recombinant subunit vaccines in Pichia pastoris.

Authors:  Man Wang; Shuai Jiang; Yefu Wang
Journal:  Bioengineered       Date:  2016-04       Impact factor: 3.269

Review 2.  Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.

Authors:  Isabelle Legastelois; Sophie Buffin; Isabelle Peubez; Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Hum Vaccin Immunother       Date:  2016-12-01       Impact factor: 3.452

Review 3.  Recent Update of COVID-19 Vaccines.

Authors:  Sameer A Jadaan; Abdul Waheed Khan
Journal:  Adv Pharm Bull       Date:  2021-10-04

4.  Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1.

Authors:  Jungsoon Lee; Zhuyun Liu; Wen-Hsiang Chen; Junfei Wei; Rakhi Kundu; Rakesh Adhikari; Joanne Altieri Rivera; Portia M Gillespie; Ulrich Strych; Bin Zhan; Peter J Hotez; Maria Elena Bottazzi
Journal:  Appl Microbiol Biotechnol       Date:  2021-05-07       Impact factor: 4.813

Review 5.  Molecular design for recombinant adeno-associated virus (rAAV) vector production.

Authors:  Juan Jose Aponte-Ubillus; Daniel Barajas; Joseph Peltier; Cameron Bardliving; Parviz Shamlou; Daniel Gold
Journal:  Appl Microbiol Biotechnol       Date:  2017-12-04       Impact factor: 4.813

Review 6.  Pichia pastoris: A highly successful expression system for optimal synthesis of heterologous proteins.

Authors:  Mohsen Karbalaei; Seyed A Rezaee; Hadi Farsiani
Journal:  J Cell Physiol       Date:  2020-02-14       Impact factor: 6.384

Review 7.  Sneaking Out for Happy Hour: Yeast-Based Approaches to Explore and Modulate Immune Response and Immune Evasion.

Authors:  Gaëlle Angrand; Alicia Quillévéré; Nadège Loaëc; Chrysoula Daskalogianni; Anton Granzhan; Marie-Paule Teulade-Fichou; Robin Fahraeus; Rodrigo Prado Martins; Marc Blondel
Journal:  Genes (Basel)       Date:  2019-08-31       Impact factor: 4.096

8.  Saccharomyces cerevisiae exhibiting a modified route for uptake and catabolism of glycerol forms significant amounts of ethanol from this carbon source considered as 'non-fermentable'.

Authors:  Maximilian R Aßkamp; Mathias Klein; Elke Nevoigt
Journal:  Biotechnol Biofuels       Date:  2019-10-31       Impact factor: 6.040

9.  Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus.

Authors:  Jeffrey C Boyington; M Gordon Joyce; Mallika Sastry; Guillaume B E Stewart-Jones; Man Chen; Wing-Pui Kong; Joan O Ngwuta; Paul V Thomas; Yaroslav Tsybovsky; Yongping Yang; Baoshan Zhang; Lei Chen; Aliaksandr Druz; Ivelin S Georgiev; Kiyoon Ko; Tongqing Zhou; John R Mascola; Barney S Graham; Peter D Kwong
Journal:  PLoS One       Date:  2016-07-27       Impact factor: 3.240

Review 10.  The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.

Authors:  Sonali Kochhar; Denny Kim; Jean-Louis Excler; Richard C Condit; James S Robertson; Stephen Drew; Mike Whelan; David Wood; Patricia E Fast; Marc Gurwith; Bettina Klug; Najwa Khuri-Bulos; Emily R Smith; Robert T Chen
Journal:  Vaccine       Date:  2020-07-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.